Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
02/20/2017 02/21/2017 02/22/2017 02/23/2017 02/24/2017 Date
68.04(c) 68.2(c) 68.55(c) 66.68(c) 66.33(c) Last
193 816 343 012 374 599 671 480 511 468 Volume
-0.06% +0.24% +0.51% -2.73% -0.52% Change
More quotes
Financials (€)
Sales 2017 4 318 M
EBIT 2017 898 M
Net income 2017 581 M
Debt 2017 560 M
Yield 2017 2,01%
Sales 2018 4 514 M
EBIT 2018 1 084 M
Net income 2018 719 M
Finance 2018 97,6 M
Yield 2018 2,09%
P/E ratio 2017 20,43
P/E ratio 2018 16,41
EV / Sales2017 3,12x
EV / Sales2018 2,84x
Capitalization 12 902 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
02/23Earnings Release
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
02/24 UCB : Transparency notifications BlackRock, Inc.
02/24 UCB : Transparency notification Wellington Management Group LLP
02/23 UCB FULL YEAR REPORT 2016 : UCB demonstrates continued top and …
02/16 UCB : Transparency notification
02/09 UCB : Transparency notifications
02/08 UCB : Transparency notifications
01/25 UCB : Transparency notifications
01/19 UCB : files BRIVIACT® (brivaracetam) CV in the U.S. as …
01/19 UCB : Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy &h..
01/18 UCB : Transparency notification
More news
Sector news : Pharmaceuticals - NEC
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/23 Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
More sector news : Pharmaceuticals - NEC
Latest Tweets
02:28a#EquityResearch UCB S.A. 2016 Q4 - Results - Earnings Call Slides $UCBJF  
02:25aUCB S.A. 2016 Q4 - Results - Earnings Call Slides  
02/23UCB Full Year Report 2016: UCB demonstrates continued top and …  
02/17Y'all, we have such a good show tonight! Plus, we have a fun drop in! 7:30 at..
1
02/16I liked a @YouTube video from @theyoungturks
4
More tweets
Qtime:25
News from SeekingAlpha
02/24 UCB S.A. 2016 Q4 - Results - Earnings Call Slides
02/24 UCB's (UCBJF) CEO Jean-Christophe Tellier on Q4 2016 Results - Earnings Call ..
02/23 UCB S.A. reports FY results
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
2016 Marketing application filed in Japan for osteoporosis candidate romosozumab
Advertisement
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 77,0 €
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB8.90%13 612
JOHNSON & JOHNSON5.63%333 891
ROCHE HOLDING LTD.5.98%210 192
PFIZER INC.4.86%207 902
NOVARTIS AG4.72%202 648
MERCK & CO., INC.11.86%182 412
More Results